Binding targets of SUZ12 and EZH2 were consistently enriched across all five cancer types, while targets of REST and SMAD4 were enriched in all cancers except for clear cell renal cell carcinoma (Fig. 3d). The gene discussed is EZH2; the disease is cancer.